We are presently representing clients who have been injured by several different defective medical products, including the diabetes drug Actos and transvaginal mesh. As part of our work, we have studied much of the available medical research.

Recently, I viewed an interesting discussion on an issue important in the medical research. The issue is: Why are negative medical tests often concealed or not published? These negative tests are important to our safety. For example, the investigation of Actos and its connection to bladder cancer, has raised significant concerns that the manufacturer Takeda concealed tests. Our research and representation of many women with mesh implants has led us to the clear question of why these mesh products were ever marketed without sufficient testing provided to the FDA.

In the following video, the speaker talks about “publication bias” which he describes as the failure to publish negative test results. The speaker describes how this failure raises serious medical and safety concerns. As patients, we need to know whether a medication or medical device may be dangerous. Here is the video:

 

Our system does not encourage researchers to publish important negative results. Drug companies pay huge sums of money to doctors and researchers. In return, the companies get their drugs through the FDA approval process. Then, they get their drugs and products provided to patients. The profit from just a few years of selling a defective drug is huge. Sometimes, the dangerous defects in these products are only revealed years later after patients begin to suffer personal injuries and deaths. These patients are our family members and neighbors. We deserve better from our FDA and medical professionals.